Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Immunosuppression

Immunosuppression

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Immunosuppression

19 trials tracked for Immunosuppression: 6 in phase 3 or 4 and 1 with published results.

19Trials tracked
6Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 6 Phase 2 5 Other / NA 8
  1. Phase 4 Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients Completed
  2. Phase 4 Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS Completed
  3. Phase 4 Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant Completed
  4. Phase 4 Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients Completed
  5. Phase 4 Immune Monitoring to Facilitate Belatacept Monotherapy Completed
  6. Phase 4 Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients Completed
Show 13 more trials
  1. Phase 2 Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients Completed
  2. Phase 2 Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis Completed
  3. Phase 2 NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia Completed
  4. Phase 2 Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients Completed
  5. Phase 2 Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations Completed
  6. N/A Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients Completed
  7. N/A Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression Completed
  8. N/A HLA-Identical Sibling Renal Transplant Tolerance Completed
  9. N/A A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients Completed
  10. N/A A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children Completed
  11. N/A The Differential Effects of 3 Different Immunosuppressive Completed
  12. N/A Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients Completed
  13. N/A Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation. Completed

Showing the 19 most-cited and recently-updated of 19 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Immunosuppression: what the trials found

Clinical evidence regarding Tacrolimus demonstrates specific pharmacokinetic and safety profiles. The median sublingual to oral ratio was found to be 1.02 2. In a large cohort, Tacrolimus was associated with a 98% one-year survival rate post-transplant and mean ISHLT biopsy scores of 0.62 to 0.7 over the first year (p=0.44) 6. Additionally, Tacrolimus administration was associated with 0% acute allograft rejection in a study monitoring medication adherence over 6 months 14.

Alternative and extended-release formulations show specific clinical outcomes. The Tacrolimus Extended Release Capsule reached therapeutic trough goals in 10 to 15 days 3. Mycophenolate sodium was evaluated as an intervention 5, while Myfortic was utilized in studies assessing gastrointestinal side effects and quality of life (GSRS) scores [15, 16].

Everolimus showed significant results in both cytokine evaluation (p<0.05) and renal function assessment (p<0.05) 4. Studies also evaluated the impact of immunosuppression reduction 1.

Recent results — preliminary, needs further review

  • Infusion of Donor Hematopoietic Stem Cells and Campath-1H was associated with the ability to withdraw immunosuppression in 6 patients over 24 months post-transplant 12.
  • NVX-CoV2372 showed 0% seronegative participants at baseline who remained seronegative, alongside a decrease in interferon gamma responses from month 1 to month 6 [-0.625] 7.

For the clinician treating this condition

  • Tacrolimus is associated with high one-year survival rates (98%) and stable biopsy scores post-transplant 6.
  • Everolimus demonstrated statistically significant improvements in renal function and cytokine levels 4.
  • Myfortic was evaluated specifically for its impact on gastrointestinal side effects and quality of life 16.

AI synthesis of 10 cited trials, updated Jun 24, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Nearly half of immunosuppressed residents engaged in mold cleanup after Hurricane Harvey
Allergy & Immunology
Nearly half of immunosuppressed residents engaged in mold cleanup after Hurricane Harvey Nearly half of vulnerable residents did mold cleanup after Hurricane Harvey
An observational study of immunosuppressed residents in Hurricane Harvey-affected Houston found 49% engaged in cleanup activities in water-d…
Nearly half of vulnerable Houston residents cleaned up mold after Hurricane Harvey, exposing themselves to potential health risks in damaged…
CDC Apr 4, 2026